FULCRUM THERAPEUTICS, INC. Revenue from Contract with Customer, Including Assessed Tax
FULCRUM THERAPEUTICS, INC. (FULC) reported Revenue from Contract with Customer, Including Assessed Tax of $0 for the 12-month period ending 2025-12-31, per its S-4 filed 2026-09-02.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2026-09-02
- FULCRUM THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2025-12-31 was $0.00.
- FULCRUM THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2025-09-30 was $0.00.
- FULCRUM THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for fiscal 2023 was $2.81M, a 55.77% decline from fiscal 2022.
- FULCRUM THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for fiscal 2022 was $6.34M, a 66.90% decline from fiscal 2021.
- FULCRUM THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for fiscal 2021 was $19.16M, a 117.19% increase from fiscal 2020.
- FULCRUM THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for fiscal 2020 was $8.82M.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | $0.00 derived: sum of 2 quarters · filed 2026-09-02 | $0.00 derived: sum of 3 quarters · filed 2026-09-02 | $0.00 S-4 · filed 2026-09-02 |
| 2025-09-30 | $0.00 10-Q · filed 2025-10-29 | $0.00 derived: sum of 2 quarters · filed 2025-10-29 | $0.00 10-Q · filed 2025-10-29 | |
| 2025-06-30 | $0.00 10-Q · filed 2025-07-29 | $0.00 10-Q · filed 2025-07-29 | ||
| 2024-12-31 | $0.00 derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | $0.00 derived: sum of 2 quarters · filed 2026-09-02 | $80.00M derived: sum of 3 quarters · filed 2026-09-02 | $80.00M S-4 · filed 2026-09-02 |
| 2024-09-30 | $0.00 10-Q · filed 2025-10-29 | $80.00M derived: sum of 2 quarters · filed 2025-10-29 | $80.00M 10-Q · filed 2025-10-29 | $80.87M derived: sum of 4 quarters · filed 2025-10-29 |
| 2024-06-30 | $80.00M 10-Q · filed 2025-07-29 | $80.00M 10-Q · filed 2025-07-29 | $80.87M derived: sum of 3 quarters · filed 2025-07-29 | $81.63M derived: sum of 4 quarters · filed 2025-07-29 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-13 | $871.00K derived: sum of 2 quarters · filed 2025-02-25 | $1.63M derived: sum of 3 quarters · filed 2025-02-25 | $2.51M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-12-31 | $871.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $1.63M derived: sum of 2 quarters · filed 2025-02-25 | $2.51M derived: sum of 3 quarters · filed 2025-02-25 | $2.81M 10-K · filed 2025-02-25 |
| 2023-09-30 | $759.00K 10-Q · filed 2024-11-13 | $1.64M derived: sum of 2 quarters · filed 2024-11-13 | $1.93M 10-Q · filed 2024-11-13 | $2.62M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $880.00K 10-Q · filed 2024-07-31 | $1.18M 10-Q · filed 2024-07-31 | $1.86M derived: sum of 3 quarters · filed 2024-07-31 | $3.04M derived: sum of 4 quarters · filed 2024-07-31 |
| 2023-03-31 | $295.00K 10-Q · filed 2024-05-13 | $980.00K derived: sum of 2 quarters · filed 2024-05-13 | $2.16M derived: sum of 3 quarters · filed 2024-05-13 | $4.04M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $685.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.87M derived: sum of 2 quarters · filed 2024-02-27 | $3.75M derived: sum of 3 quarters · filed 2024-02-27 | $6.34M 10-K · filed 2024-02-27 |
| 2022-09-30 | $1.18M 10-Q · filed 2023-11-07 | $3.06M derived: sum of 2 quarters · filed 2023-11-07 | $5.66M 10-Q · filed 2023-11-07 | $10.71M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $1.88M 10-Q · filed 2023-08-03 | $4.47M 10-Q · filed 2023-08-03 | $9.53M derived: sum of 3 quarters · filed 2023-08-03 | $14.47M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $2.59M 10-Q · filed 2023-05-15 | $7.65M derived: sum of 2 quarters · filed 2023-06-26 | $12.59M derived: sum of 3 quarters · filed 2023-06-26 | $16.97M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-12-31 | $5.06M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-26 | $9.99M derived: sum of 2 quarters · filed 2023-06-26 | $14.37M derived: sum of 3 quarters · filed 2023-06-26 | $19.16M 10-K/A · filed 2023-06-26 |
| 2021-09-30 | $4.93M 10-Q · filed 2022-11-08 | $9.32M derived: sum of 2 quarters · filed 2022-11-08 | $14.11M 10-Q · filed 2022-11-08 | $18.33M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-06-30 | $4.38M 10-Q · filed 2022-08-11 | $9.17M 10-Q · filed 2022-08-11 | $13.39M derived: sum of 3 quarters · filed 2023-06-26 | $15.24M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-03-31 | $4.79M 10-Q · filed 2022-05-09 | $9.01M derived: sum of 2 quarters · filed 2023-06-26 | $10.86M derived: sum of 3 quarters · filed 2023-06-26 | $12.86M derived: sum of 4 quarters · filed 2023-06-26 |
| 2020-12-31 | $4.22M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-26 | $6.07M derived: sum of 2 quarters · filed 2023-06-26 | $8.07M derived: sum of 3 quarters · filed 2023-06-26 | $8.82M 10-K/A · filed 2023-06-26 |
| 2020-09-30 | $1.85M 10-Q · filed 2021-11-04 | $3.85M derived: sum of 2 quarters · filed 2021-11-04 | $4.60M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $2.00M 10-Q · filed 2021-08-10 | $2.75M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $750.00K 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |